The effects of anagrelide on human megakaryocytopoiesis

Lawrence A. Solberg, Ayalew Tefferi, Karl J. Oles, Jerzy S. Tarach, Robert M. Petitt, Lee A. Forstrom, Murray N. Silverstein

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


Anagrelide, an inhibitor of platelet aggregation, decreases the number of platelets in normal subjects and in patients with myeloproliferative disorders. We describe studies aimed at discovering the general mechanism(s) by which anagrelide acts. We examined three hypotheses: (1) anagrelide shortens platelet survival, (2) anagrelide inhibits the proliferation of megakaryocytic-committed progenitor cells (CFU-M), and (3) anagrelide inhibits maturation of megakaryocytes. We observed that anagrelide did not shorten platelet survival. Proliferation of CFU-M in vivo was not affected by anagrelide, although high concentrations of anagrelide inhibited CFU-M in vitro. In-vivo and in-vitro anagrelide altered the maturation of megakaryocytes, causing a decrease in their size and changing other morphometric features. We conclude that anagrelide decreases the number of platelets primarily by interfering with the maturation of megakaryocytes.

Original languageEnglish (US)
Pages (from-to)174-180
Number of pages7
JournalBritish journal of haematology
Issue number1
StatePublished - 1997


  • Digital imaging analysis
  • Glycoprotein IIb/IIIa
  • Haemopoiesis
  • Megakaryocyte
  • Stem cells

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The effects of anagrelide on human megakaryocytopoiesis'. Together they form a unique fingerprint.

Cite this